A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy- N,N -dimethyltryptamine) in patients with treatment-resistant depression
Claire T. Roberts, Mathieu Seynaeve, Anna O. Ermakova, Fiona Dunbar, Hattie Wells, Adeep Puri, Catherine Bird, James Rucker
Journal of Psychopharmacology February 27, 2026 DOI: 10.1177/02698811261420087 via OpenAlex
Summary
AI-generated from the abstractA single dose of BPL-003, a psychedelic drug given as a nasal spray, was safe in people with treatment-resistant depression. Depression scores dropped quickly and stayed lower for 12 weeks, suggesting the drug may help this hard-to-treat condition. Larger controlled trials are needed.
Study at a glance
| Characteristics | Clinical trial Open-label Peer reviewed |
|---|---|
| Population | Treatment-resistant depression (TRD) population |
| Intervention | BPL-003 |
| Duration | 12 weeks |
| Topics | Depression |
| Keywords | Depression economics Nasal administration Adverse effect |
| Key finding | A single dose of BPL-003 produced a rapid and sustained reduction in MADRS score over 12 weeks in people with treatment-resistant depression. |
Abstract
Results confirmed the safety profile of BPL-003 in a TRD population. A rapid and sustained reduction in MADRS score was observed over 12 weeks, suggesting BPL-003 could be beneficial in TRD, warranting investigation in larger controlled trials.